Katsufumi Nishida, MD
Pulmonary Disease · Honolulu, HINPI 1912118159
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (47.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 65.9% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $5,480, 3.4 times the $1,615 reported in 2022.
Across 36 payments — averaging $233.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- Olympus Corporation Of The Americas$1K
- Johnson & Johnson$915
- Medical Device Business Services, Inc.$721
- Inspire Medical Systems, Inc.$27
- GSK$23
- plus $19 from 1 others
What the payments were for
- Travel & lodging$3,86746%
- Food & beverage$5366%
- Education$4,00048%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 11 | $5,534 |
| Olympus Corporation Of The Americas | 9 | $1,165 |
| Johnson & Johnson | 7 | $915 |
| Medical Device Business Services, Inc. | 6 | $721 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| GSK | 1 | $23 |
| Itamar Medical Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$5,349
- Spiration Valve System$1,031
- Monarch Platform$796
How this compares
$8,404 in reported general payments places this provider in the 70th percentile of 44 pulmonary disease providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 335 | $291,277 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 101 | $74,413 |
| Spiriva RespimatTiotropium Bromide | 98 | $70,971 |
| NucalaMepolizumab | 15 | $55,636 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 77 | $39,679 |
| Spiriva HandihalerTiotropium Bromide | 26 | $20,347 |
| Breo ElliptaFluticasone/Vilanterol | 42 | $19,873 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 21 | $17,031 |
| Incruse ElliptaUmeclidinium Bromide | 37 | $15,965 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $14,193 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $10,767 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 40 | $8,786 |
| Pirfenidone | 11 | $7,371 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 36 | $7,323 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 246 | $6,920 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $23 | $400,998463 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 44 pulmonary disease providers in Hawaii.
Other pulmonary disease in Honolulu
- Takkin LoHonolulu$324K
- Bradley TokeshiHonolulu$41K
- Ernie YimHonolulu$20K
- Eric CrawleyHonolulu$17K
- Samuel EvansHonolulu$15K
- Ronson SatoHonolulu$14K
- Alvin FuruikeHonolulu$10K
- James YangHonolulu$8K
- Sheri Shimizu-SaitoHonolulu$8K
- Jennifer KayaHonolulu$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.